Forward Pharma A/S Plans Annual Dividend of $22.90 (FWP)
Forward Pharma A/S (NASDAQ:FWP) declared an annual dividend on Thursday, August 24th, NASDAQ reports. Stockholders of record on Thursday, September 7th will be given a dividend of 22.903 per share by the biotechnology company on Monday, September 11th. The ex-dividend date of this dividend is Wednesday, September 6th.
Forward Pharma A/S (FWP) traded up 0.83% during trading on Friday, hitting $24.35. The stock had a trading volume of 8,378 shares. The company’s 50 day moving average is $22.80 and its 200 day moving average is $22.96. The firm’s market cap is $1.15 billion. Forward Pharma A/S has a 52-week low of $14.89 and a 52-week high of $33.00.
WARNING: “Forward Pharma A/S Plans Annual Dividend of $22.90 (FWP)” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/08/25/forward-pharma-as-plans-annual-dividend-of-22-90-fwp.html.
FWP has been the topic of several recent analyst reports. BidaskClub raised shares of Forward Pharma A/S from a “hold” rating to a “buy” rating in a research note on Thursday, August 10th. ValuEngine raised shares of Forward Pharma A/S from a “sell” rating to a “hold” rating in a research note on Saturday, June 17th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $24.00.
Forward Pharma A/S Company Profile
Forward Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in the development of FP187, a formulation of dimethyl fumarate (DMF) for the treatment of several inflammatory and neurological indications, including multiple sclerosis (MS). The Company’s clinical candidate, FP187, is under development for the treatment of relapsing remitting MS (RRMS) and other immune disorders, such as psoriasis.
Receive News & Stock Ratings for Forward Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forward Pharma A/S and related stocks with our FREE daily email newsletter.